Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found
Articles 1 records found  
1.
11 p, 1.6 MB Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 / Eron, J. J. (University of North Carolina School of Medicine) ; Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ; Cunningham, D. (Pueblo Family Physicians) ; Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Post, F. (King's College Hospital NHS Foundation Trust) ; De Wit, Stéphane (Université Libre de Bruxelles) ; Lathouwers, E. (Janssen Pharmaceutica NV) ; Hufkens, V. (Janssen Pharmaceutica NV) ; Jezorwski, J. (Janssen Research & Development) ; Petrovic, R. (Janssen Pharmaceutica NV) ; Brown, K. (Janssen Pharmaceutica NV) ; Van Landuyt, E. (Janssen Pharmaceutica NV) ; Opsomer, M. (Janssen Pharmaceutica NV) ; De Wit, Stéphane (Université Libre de Bruxelles) ; Florence, E. (Institute of Tropical Medicine) ; Moutschen, M. (Liège University Hospital (Bèlgica)) ; Van Wijngaerden, E. (University Hospitals Leuven (Bèlgica)) ; Vandekerckhove, L. (Ghent University Hospital. (Bèlgica)) ; Vandercam, B. (AIDS Reference center. Cliniques Universitaires Saint-Luc) ; Brunetta, J. (Maple Leaf Medical Clinic) ; Conway, B. (Vancouver Infectious Diseases Center) ; Klein, M. (Division of Infectious Diseases. Faculty of Medicine. McGill University Health Centre) ; Murphy, D. (Institut national de santé publique du Québec) ; Rachlis, A. (Sunnybrook Health Sciences Centre) ; Shafran, S. (Department of Medicine. University of Alberta) ; Walmsley, S. (University Health Network) ; Ajana, F. (Infectious Diseases Department. Tourcoing Hospital) ; Cotte, L. (Hospices Civils de Lyon. Hôpital de la Croix-Rousse) ; Girardy, P. M. (University Pierre & Marie Curie) ; Katlama, C. (HIV Clinical Research Unit) ; Molina, J. M. (Department of Infectious Diseases. St-Louis Hospital APHP. University of Paris Diderot) ; Poizot-Martin, I. (Clinical Immuno-Hematology Department. Aix-Marseille University. Sainte-Marguerite University Hospital and Inserm U912) ; Raffi, F. (CHU Hôtel Dieu) ; Rey, D. (Le Trait d'Union. HIV-Infection Care Center. Hôpitaux Universitaires de Strasbourg) ; Reynes, J. (University Hospital of Montpellier (França)) ; Teicher, E. (Infectious Diseases Department. APHP. Hôpital Bicêtre) ; Yazdanpanah, Y. ; Gasiorowski, J. (Independent Laboratory for Monitoring Infections among Drug Users at the Department of Infectious Diseases. Liver Disease and Acquired Immune Deficiencies. Wroclaw Medical University) ; Halota, W. (Department of Infectious Diseases and Hepatology. Nicolaus Copernicus University) ; Horban, A. (Medical University of Warsaw. Department for Adult's Infectious Diseases) ; Piekarska, A. (Department of Infectious Diseases and Hepatology. Medical University of Lodz) ; Witor, A. (Regional Hospital. Out-Patient's Clinic for Immune Deficiency) ; Arribas, J. R. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Perez-Valero, I. (Hospital Universitario La Paz (Madrid)) ; Berenguer, Juan (Hospital General Universitario Gregorio Marañón) ; Casado, José A. (Hospital Universitario Ramón y Cajal (Madrid)) ; Gatell, J. M. (Infectious Diseases Department. HCB) ; Gutiérrez, Félix (Hospital General Universitario de Elche) ; Galindo, María José (Hospital Clínic Universitari (València)) ; Gutiérrez Macià, Mª Del Mar (Institut d'Investigació Biomèdica Sant Pau) ; Iribarren, J. A. (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ; Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya)) ; Negredo Puigmal, Eugènia. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Pineda, J. A. (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; Podzamczer, Daniel (Institut d'Investigació Biomèdica de Bellvitge) ; Sogorb, J. P. (Hospital Universitario 12 de Octubre (Madrid)) ; Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Ricart, C. (Department of Microbiology. School of Medicine. University of Valencia) ; Rivero, Antonio (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Santos Gil, I. (Hospital Universitario de la Princesa (Madrid)) ; Blaxhult, A. (Department of Infectious Diseases. Venhälsan. Södersjukhuset) ; Flamholc, L. (Skåne University Hospital (Suècia)) ; Gisslèn, M. (Department of Infectious Diseases. University of Gothenburg) ; Thalme, A. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Fehr, J. (University Hospital Zurich (Suïssa)) ; Rauch, A. (Bern University Hospital) ; Stoeckle, M. (University Hospital Basel (Basilea, Suïssa)) ; Clarke, A. (Claude Nicol Centre. Royal Sussex County Hospital. Brighton and Sussex University Hospitals NHS Trust) ; Gazzard, B. G. (St. Stephen's Centre. Department of HIV/Genito-Urinary Medicine. Chelsea and Westminster Hospital) ; Johnson, M. A. (Queen Mary University) ; Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ; Post, F. (King's College Hospital NHS Foundation Trust) ; Ustianowski, Andrew (Regional Infectious Diseases Unit. North Manchester General Hospital) ; Waters, L. (University College London Hospital) ; Bailey, J. (Department of Medicine. Johns Hopkins University School of Medicine) ; Benson, P. (Be Well Medical) ; Bhatti, L. (AIDS Healthcare Foundation) ; Brar, I. (Henry Ford Hospital) ; Bredeek, U. F. (Metropolis Medical PC) ; Brinson, C. (Central Texas Clinical Research) ; Crofoot, G. (The Crofoot Research Center) ; Cunningham, D. (Pueblo Family Physicians) ; DeJesus, E. (Pueblo Family Physicians) ; Dietz, C. (Orlando Immunology Center) ; Dretler, R. (HIV Medicine. Kansas City Free Health Clinic) ; Eron, J. (Infectious Disease Specialists of Atlanta) ; Felizarta, F. (Private Practice) ; Fichtenbaum, C. (University of Cincinnati College of Medicine) ; Gallant, J. (Southwest CARE Center) ; Gathe, J. (Therapeutic Concepts) ; Hagins, D. (Georgia Department of Public Health. Chatham Care Center) ; Henn, S. (Whitman-Walker Health) ; Henry, W. K. (Department of Medicine. University of Minnesota Washington University School of Medicine) ; Huhn, G. (Ruth M. Rothstein CORE Center) ; Jain, M. (Department of Internal Medicine. University of Texas Southwestern Medical Center) ; Lucasti, C. (South Jersey Infectious Disease) ; Martorell, C. (Infectious Disease and The Research Institute) ; McDonald, C. (Tarrant County Infectious Disease Associates) ; Mills, A. (Southern California Men's Medical Group) ; Morales-Ramirez, J. (Clinical Research Puerto Rico Inc.) ; Mounzer, K. (Philadelphia FIGHT) ; Nahass, R. (ID Care) ; Olivet, H. (Community Research Initiative of New England) ; Osiyemi, O. (Triple O Research Institute PA) ; Prelutsky, D. (Department of Internal Medicine. Washington University School of Medicine) ; Ramgopal, M. (Midway Immunology Center. Fort Pierce) ; Rashbaum, B. (Capital Medical Associates) ; Richmond, G. (Broward General Medical Center) ; Ruane, P. (Ruane Clinical Research Group) ; Scarsella, A. (Pacific Oaks Medical Group) ; Scribner, A. (DCOL Center for Clinical Research) ; Shalit, P. (Peter Shalit MD and Associates) ; Shamblaw, D. (La Playa Medical Group) ; Slim, J. (Department of Infectious Diseases. Seton Hall University) ; Tashima, K. (The Miriam Hospital. Warren Alpert Medical School of Brown University) ; Voskuhl, G. (AIDS Arms. Inc.) ; Ward, D. (Dupont Circle Physicians Group) ; Wilkin, A. (Wake Forest School of Medicine) ; de Vente, J. (Living Hope Foundation) ; Universitat Autònoma de Barcelona
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. [...]
2019 - 10.1016/j.antiviral.2019.104543
Antiviral Research, Vol. 170 (october 2019) , p. 104543  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.